KR20240111823A - 항-cd47 항체 및 이의 사용 방법 - Google Patents

항-cd47 항체 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240111823A
KR20240111823A KR1020247017377A KR20247017377A KR20240111823A KR 20240111823 A KR20240111823 A KR 20240111823A KR 1020247017377 A KR1020247017377 A KR 1020247017377A KR 20247017377 A KR20247017377 A KR 20247017377A KR 20240111823 A KR20240111823 A KR 20240111823A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247017377A
Other languages
English (en)
Korean (ko)
Inventor
팡융 두
피터 페이지 루오
얀 리
빈 차이
지안펭 시
장춘 쉬
아아론 응우옌
쑹마오 정
구이중 리우
정시 다이
Original Assignee
아다젠 프라이빗 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아다젠 프라이빗 리미티드 filed Critical 아다젠 프라이빗 리미티드
Publication of KR20240111823A publication Critical patent/KR20240111823A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247017377A 2021-10-27 2022-10-27 항-cd47 항체 및 이의 사용 방법 Pending KR20240111823A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/126597 2021-10-27
PCT/CN2021/126597 WO2023070353A1 (en) 2021-10-27 2021-10-27 Anti-cd47 antibodies and methods of use thereof
PCT/CN2022/127875 WO2023072177A1 (en) 2021-10-27 2022-10-27 Anti-cd47 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20240111823A true KR20240111823A (ko) 2024-07-17

Family

ID=86160307

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017377A Pending KR20240111823A (ko) 2021-10-27 2022-10-27 항-cd47 항체 및 이의 사용 방법

Country Status (9)

Country Link
US (1) US20240417463A1 (https=)
EP (1) EP4423138A4 (https=)
JP (1) JP2024542978A (https=)
KR (1) KR20240111823A (https=)
CN (1) CN118434769A (https=)
AU (1) AU2022376756A1 (https=)
CA (1) CA3235611A1 (https=)
TW (1) TW202334216A (https=)
WO (2) WO2023070353A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
TW202517683A (zh) * 2023-07-20 2025-05-01 美商艾克塞里克斯公司 可活化之ror結合劑及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2477648B1 (en) * 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
US9517276B2 (en) * 2013-06-04 2016-12-13 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
EP3668897B1 (en) * 2017-08-18 2024-06-05 Centessa Pharmaceuticals (UK) Limited Binding agents
KR20200091901A (ko) * 2017-12-01 2020-07-31 시애틀 지네틱스, 인크. 암을 치료하기 위한 cd47 항체 및 이의 용도
EP3802599B1 (en) * 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
MA53333A (fr) * 2018-07-31 2021-11-03 Amgen Inc Formulations pharmaceutiques d'anticorps masqués
US20220233709A1 (en) * 2019-06-05 2022-07-28 Seagen Inc. Masked Antibody Formulations
US20220306727A1 (en) * 2019-06-05 2022-09-29 Seagen Inc. Methods of Purifying Masked Antibodies
EP4034171A1 (en) * 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof

Also Published As

Publication number Publication date
EP4423138A4 (en) 2026-03-04
TW202334216A (zh) 2023-09-01
WO2023072177A1 (en) 2023-05-04
JP2024542978A (ja) 2024-11-19
CN118434769A (zh) 2024-08-02
WO2023070353A1 (en) 2023-05-04
US20240417463A1 (en) 2024-12-19
EP4423138A1 (en) 2024-09-04
CA3235611A1 (en) 2023-05-04
AU2022376756A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
JP7678841B2 (ja) 抗ｃｔｌａ４抗体ならびにその作製及び使用方法
AU2019214189B2 (en) Activatable antibodies and methods of making and using thereof
AU2019306628B2 (en) Anti-CD112R compositions and methods
EP3503920B1 (en) Anti-ctla4 antibodies
US10808030B2 (en) Anti-HCTLA-4 antibodies
US10494436B2 (en) Anti-PD-1 antibodies
TWI772275B (zh) 特異性結合pd-1、tim-3或pd-1與tim-3之抗體及其用途
WO2023072177A1 (en) Anti-cd47 antibodies and methods of use thereof
US20240209092A1 (en) Combination therapies for treating cancer
TWI888925B (zh) 抗ctla4抗體及其製備及使用方法
BR122023018935B1 (pt) Anticorpo, polinucleotídeo, vetor, célula hospedeira bacteriana, método de produção de um anticorpo, composição farmacêutica e uso do anticorpo
HK40006481B (en) Anti-ctla4 antibodies
HK40006481A (en) Anti-ctla4 antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000